Skip to main content
. 2016 Dec 20;129(24):2899–2906. doi: 10.4103/0366-6999.195461

Figure 2.

Figure 2

Mean change from baseline in total International Prostate Symptom Score (IPSS) (a), IPSS storage subscale (b), IPSS voiding subscale (c), and IPSS-quality of life (QoL) (d) of the four treatment groups. *P < 0.05 versus placebo; P < 0.05 versus tamsulosin; P < 0.05 versus tolterodine extended release (ER).